Eluxadoline is a mu-opioid receptor agonist, kappa opioid receptor agonist & delta opioid receptor antagonist. Eluxadoline works directly in intestine to reduce peristalsis, also makes the nerves in intestine less sensitive to stimulation.

Eluxadoline is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

The recommended dosage in adults is 100 mg twice daily taken with food.

The recommended dosage is 75 mg twice daily taken with food in patients who:

• are unable to tolerate the 100 mg dose.
• are receiving concomitant OATP1B1 inhibitors.
• have mild or moderate hepatic impairment.

Discontinue Eluxadoline in patients who develop severeconstipation.

If a dose is missed, take the next dose at the regular time; do not take 2 doses at once

Known or suspected biliary duct obstruction, sphincter of oddi disease or dysfunction & pancreatitis.

Most common adverse reactions are constipation, nausea and abdominal pain.

Sphincter of Oddi spasm and Pancreatitis.

Patients who should be monitored closely-

• without a gallbladder
• with new or worsening abdominal pain
• with nausea and vomiting
• with acute biliary pain
• with liver or pancreatic enzyme elevation

Use in Special Populations

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Hepatic Impairment: It is contraindicated in patients with severe hepatic impairment.

Pregnancy & Lactation

Pregnancy: Not established.

Lactation: Not established.